Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
View:
Post by Riverfolk on Jun 27, 2023 9:38am

News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA

June 27 (Reuters) - Arch Biopartners Inc:

* ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA TO PROCEED WITH PHASE II ACUTE KIDNEY INJURY TRIAL

* ARCH BIOPARTNERS INC - CS-AKI TRIAL HAS PLANS TO RECRUIT UP TO 240 PATIENTS

* ARCH BIOPARTNERS INC - PATIENT RECRUITMENT FOR CS-AKI TRIAL IS EXPECTED TO BEGIN IN FALL OF 2023
Comment by Riverfolk on Jun 27, 2023 10:17am
Recent funding contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) announced by the Company in March 2023, will significantly help cover the costs of this Phase II trial.
Arch Biopartners Inc